| http://www.w3.org/ns/prov#value | - Those approvals include the treatment of juvenile cerebral palsy in 52 countries and adult spasticity in 36 countries, although those indications are nor regulated in the USA. Other uses of BTX-A unregulated in the USA include primary headaches like migraines, myofascial pain, achalasia, excessive sweating disorders, and sialorrhea associated with conditions such as cerebral palsy and Parkinson's
|
